Showing results (111-120 of 121) with videos related to
Sort By:
Pageof 13
Bioorganic & Medicinal Chemistry Letters|November 18, 2005
Piperazinyl oxime ethers as NK-1 receptor antagonistsAdri van den Hoogenband, Jan H van Maarseveen, Andrew C McCreary, et al.Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 20, 2023
Disease associations of excessive daytime sleepiness in multiple sclerosis: A prospective studyPeter V Sguigna, Sabeen Toranian, Lauren M Tardo, et al.Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 20, 2006
SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drugAndrew C McCreary, Jeffrey C Glennon, Charles R Ashby, et al.Journal of Medicinal Chemistry|March 18, 2005
Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonistsJos H M Lange, Herman H van Stuivenberg, Hein K A C Coolen, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|January 3, 2026
Clinical and radiological outcomes of directed treatment transitions from Gilenya<sup>®</sup> to generic fingolimodMahi A Patel, Tom G Punnen, Kevin S Shan, et al.Journal of Psychopharmacology (Oxford, England)|August 21, 2025
Acute cannabidiol (CBD), tetrahydrocannabinol (THC) and their mixture (THC:CBD) exert differential effects on brain activity and blood flow in rats: A translational neuroimaging studyEilidh MacNicol, Michelle Kokkinou, Maria Elisa Serrano Navacerrada, et al.JCI Insight|March 6, 2025
CD8+ TEMRAs in severe asthma associate with asthma symptom duration and escape proliferation arrestRichard P Ramonell, Timothy B Oriss, Jessica C McCreary-Partyka, et al.Journal of Medicinal Chemistry|October 28, 2005
Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[omega-(1H-indol-3-yl)alkyl]piperazines, novel potential antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibitionPieter Smid, Hein K A C Coolen, Hiskias G Keizer, et al.Journal of Medicinal Chemistry|January 23, 2004
Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonistsJos H M Lange, Hein K A C Coolen, Herman H van Stuivenberg, et al.The Journal of Pharmacology and Experimental Therapeutics|October 16, 2009
WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activityJulie A Brennan, Radka Graf, Steven M Grauer, et al.Pageof 13